Table 1 Frequencies of somatic mutations at baseline.

From: Prospective validation of a biomarker-driven response prediction model to romiplostim in lower-risk myelodysplastic neoplasms – results of the EUROPE trial by EMSCO

Type of somatic mutation

Frequency

Non HI-P

(N = 45)

HI-P

(N = 32)

Visit

Mutation

N

%

N

%

Screening

≥1 mutation

35

77.8

25

78.1

≥2 mutations

22

48.9

18

56.3

no mutations

3

6.7

2

6.3

ABL1

0

0.0

1

3.1

ASXL1

7

15.6

2

6.3

BCOR

2

4.4

1

3.1

BRAF

0

0.0

1

3.1

CBL

2

4.4

1

3.1

CBLB

0

0.0

1

3.1

CEBPA

0

0.0

2

6.3

CUX1

1

2.2

1

3.1

DNMT3A

9

20.0

4

12.5

EZH2

5

11.1

2

6.3

FLT3

0

0.0

1

3.1

GNAS

2

4.4

0

0.0

IDH1

1

2.2

0

0.0

IDH2

1

2.2

0

0.0

KMT2A

0

0.0

2

6.3

KRAS

1

2.2

1

3.1

MPL

1

2.2

0

0.0

MYC

1

2.2

0

0.0

NF1

1

2.2

1

3.1

NPM1

1

2.2

1

3.1

NOTCH1

2

4.4

1

3.1

NRAS

2

4.4

1

3.1

PHF6

1

2.2

1

3.1

PPM1D

0

0.0

1

3.1

RAD21

0

0.0

1

3.1

RUNX1

7

15.6

7

21.9

SETBP1

0

0.0

1

3.1

SF3B1

1

2.2

2

6.3

SH2B3

1

2.2

0

0.0

SMC3

1

2.2

0

0.0

SRSF2

7

15.6

13

40.6

STAG2

3

6.7

0

0.0

TET2

11

24.4

10

31.3

TP53

2

4.4

4

12.5

U2AF1

6

13.3

3

9.4

U2AF2

1

2.2

0

0.0

WT1

1

2.2

0

0.0

ZRSR2

1

2.2

2

6.3